Dilated cardiomyopathy (DCM) and hypertrophic cardiomyopathy (HCM) are two fundamentally different diseases of heart muscle that share one thing in common: they both weaken the heart’s ability to pump blood effectively, and they both carry a risk of sudden death. The core difference is structural. In HCM, the heart muscle grows abnormally thick, especially in the wall separating the left and right ventricles. In DCM, the heart’s main pumping chamber stretches and thins, ballooning outward like an overfilled water balloon. These opposite physical changes create very different problems, require different treatments, and carry different risks, even though both conditions can trace back to genetic mutations affecting the same basic contractile machinery of the heart.
What Happens to the Heart in Each Condition
In HCM, the left ventricle’s walls become abnormally thick. Echocardiography typically identifies a septal wall thickness greater than 14 mm as a diagnostic marker, and asymmetric thickening of the septum relative to the back wall of the heart (a ratio of about 1.5 to 1) is considered a hallmark feature.1PubMed Central. Echocardiography in the Diagnosis of Cardiomyopathies: Current Status and Future Directions – Section: 3. Hypertrophic Cardiomyopathy The thickened muscle can obstruct blood flow out of the heart. In roughly two-thirds of HCM cases, the swollen septum and an abnormal movement of the mitral valve (the valve between the left atrium and left ventricle) create a physical bottleneck in the outflow tract, impeding the heart’s ability to eject blood into the aorta.2Journal of the American College of Cardiology. Dynamic subaortic obstruction in hypertrophic cardiomyopathy: Analysis by pulsed doppler echocardiography The pumping strength of each squeeze may actually be normal or even supernormal early on, but the thickened, stiff muscle does not relax well between beats, so the chamber cannot fill properly.
DCM looks almost the opposite on imaging. The left ventricle dilates, its walls thin out, and its ability to contract weakens. The ejection fraction, the percentage of blood pumped out with each beat, drops well below the normal range. As the chamber stretches, the heart tries to compensate by activating neurohormonal systems (stress hormones, the renin-angiotensin system) that initially help maintain blood pressure but eventually accelerate the damage.3PubMed. Dilated cardiomyopathy: changing pathophysiological concepts and mechanisms of dysfunction This vicious cycle of dilation, hormonal overdrive, and further dilation is the central engine of disease progression in DCM. The good news is that it is also a cycle that modern medications can interrupt, sometimes allowing the heart to partially recover its size and function, a process called reverse remodeling.4IJC Heart & Vasculature. Reverse remodeling in Dilated Cardiomyopathy: Insights and future perspectives – Section: 2.1. LVRR: a mechanistic view
Different Genetic Roots, Shared Machinery
Both HCM and DCM can be caused by mutations in genes that encode the proteins of the sarcomere, the tiny contractile unit inside every heart muscle cell. But the specific genes and types of mutations tend to differ.
In HCM, the genetics are relatively well-mapped. Two genes dominate: MYBPC3, which makes a protein called myosin-binding protein C, and MYH7, which makes the beta-myosin heavy chain. Together, mutations in these two genes account for roughly 35 to 40 percent of HCM cases, with mutations in other sarcomere genes adding another 10 to 15 percent.5PubMed Central. Hypertrophic Cardiomyopathy is a Disease of Sarcomere Proteins The discovery in the late 1980s and early 1990s that sarcomere gene mutations cause HCM was a landmark moment in cardiology.6PubMed Central. Identifying sarcomere gene mutations in hypertrophic cardiomyopathy: a personal history
DCM’s genetic landscape is broader and messier. It often has a genetic basis, but the gene list is long and still growing, so comprehensive genetic testing for DCM involves ever-expanding panels of candidate genes.7PubMed Central. Dilated Cardiomyopathy: Genetic Determinants and Mechanisms One standout gene is TTN, which encodes titin, the largest protein in the human body and the molecular spring that gives the sarcomere its elasticity. Truncating mutations in TTN show up in about 27 percent of DCM patients but in only about 1 percent of HCM patients.8PubMed Central. Truncations of titin causing dilated cardiomyopathy That difference is striking and useful: if you carry a titin-truncating variant, the odds overwhelmingly point toward a dilated phenotype, not a hypertrophic one.
It is worth noting that DCM also has many non-genetic causes. Viral infections, alcohol abuse, autoimmune processes, and certain chemotherapy drugs can all damage the heart muscle and produce a dilated, weakened ventricle.9PubMed Central. Sex-Related Differences in Dilated Cardiomyopathy with a Focus on Cardiac Dysfunction in Oncology HCM, by contrast, is almost always genetic in origin.
Symptoms and How They Differ
Both conditions can cause shortness of breath, fatigue, chest discomfort, and episodes of fainting or near-fainting, which makes the symptom overlap frustrating for patients trying to understand what is wrong. But the underlying reasons for those symptoms differ.
In HCM, breathlessness often results from the thickened, stiff ventricle struggling to relax and fill. If there is outflow obstruction, the heart has to squeeze harder against a partial blockage, which can cause exertional symptoms like chest tightness and lightheadedness that worsen during or just after exercise. A subset of patients first learns they have HCM only after a dangerous arrhythmia or a cardiac arrest during physical activity.
In DCM, breathlessness comes from the weak pump failing to move enough blood forward and, consequently, fluid backing up into the lungs. Swollen ankles, weight gain from retained fluid, and exercise intolerance are common. Because the dilated ventricle is also prone to forming blood clots along its stretched walls, stroke risk is elevated. Atrial fibrillation can develop in both conditions, though the mechanisms differ: in HCM, an enlarged left atrium from chronic pressure overload is a major driver; in DCM, the volume overload and stretched atria play the bigger role. One comparison study found that when HCM patients eventually transition into a dilated phase, their left atria tend to be even larger and atrial fibrillation even more common than in primary DCM patients, even though left ventricular size and ejection fraction are worse in the DCM group.10PubMed Central. Clinical features of the dilated phase of hypertrophic cardiomyopathy in comparison with those of dilated cardiomyopathy
How Imaging Tells Them Apart
Echocardiography is usually the first test that reveals either condition. In HCM, the echo shows thick walls and, often, the telltale systolic anterior motion (SAM) of the mitral valve, where the valve leaflet gets pulled into the outflow tract during contraction.11PubMed Central. Echocardiography in the Diagnosis of Cardiomyopathies: Current Status and Future Directions – Section: 3. Hypertrophic Cardiomyopathy In DCM, the echo shows a large, thinned, globally weakened ventricle.
Cardiac MRI adds detail that echocardiography cannot. One of its key tricks is late gadolinium enhancement (LGE), a technique that highlights scarred or fibrotic tissue. In HCM, LGE often appears as fine, patchy bright spots scattered across hypertrophied segments and at the points where the right ventricle inserts into the left.12PubMed. Utility of late gadolinium enhancement in pediatric cardiac MRI In DCM, when LGE is present, it tends to follow a mid-wall linear stripe, often in the septum. One MRI study found that DCM patients with no LGE or only localized septal LGE were able to undergo reverse remodeling with treatment, while those with extensive LGE spreading beyond the septum did not improve, behaving more like end-stage HCM patients.13PubMed. Distribution of late gadolinium enhancement in end-stage hypertrophic cardiomyopathy and dilated cardiomyopathy: differential diagnosis and prediction of cardiac outcome The pattern and extent of scar tissue on MRI have become crucial for both distinguishing the two diseases and predicting who will respond to therapy.
Sudden Cardiac Death Risk
Both DCM and HCM carry a risk of sudden cardiac death (SCD) from dangerous arrhythmias, and both may require implantable cardioverter-defibrillators (ICDs). But the risk profiles differ.
HCM is famously associated with SCD in young athletes and has long been regarded as the leading cardiac cause of sudden death in young people. MRI-based risk stratification has become central to deciding who needs a defibrillator. About half of HCM patients show some LGE on MRI, so simply having scar tissue is not enough to flag high risk. Quantifying how much scar matters: when LGE exceeds about 15 percent of total heart muscle mass, the risk of SCD roughly doubles to triples. American guidelines now include MRI scar assessment in the ICD decision-making process for borderline-risk HCM patients.14European Heart Journal Supplements. Risk stratification in cardiomyopathies (dilated, hypertrophic, and arrhythmogenic cardiomyopathy) by cardiac magnetic resonance imaging – Section: Hypertrophic cardiomyopathy
In DCM, sudden death is less predictable and harder to stratify by a single imaging marker. The overall event rate is lower than in HCM on a per-patient basis, but because DCM is more common, the absolute number of SCD events is substantial. In children with DCM, one registry study identified a combination of a very enlarged left ventricle, diagnosis before age 14, and very thin ventricular walls relative to chamber size as a set of criteria that captured the vast majority of pediatric SCD events, though with moderate specificity.15PubMed Central. Incidence of and risk factors for sudden cardiac death in children with dilated cardiomyopathy: a report from the Pediatric Cardiomyopathy Registry In adults, severely reduced ejection fraction remains the primary trigger for recommending an ICD, a criterion that does not translate neatly to children.
Treatment Strategies Go in Opposite Directions
This is where the two diseases diverge most sharply in clinical practice. The medications that form the backbone of DCM treatment can be dangerous in HCM, and vice versa.
For DCM, guideline-directed medical therapy revolves around blocking the neurohormonal overdrive that fuels the remodeling cycle. ACE inhibitors or angiotensin receptor blockers, beta-blockers, and mineralocorticoid receptor antagonists (like spironolactone) are the core regimen. In cohorts with high adherence to this combination, significant improvements in ejection fraction and survival are well documented.16The American Journal of Cardiology. Frequency of Recovery and Relapse in Patients With Nonischemic Dilated Cardiomyopathy on Guideline-Directed Medical Therapy More recently, sodium-glucose co-transporter 2 (SGLT2) inhibitors and sacubitril-valsartan have been added to the arsenal. The goal of all these drugs is to reduce the workload on the dilated ventricle, slow or reverse the stretching, and keep the patient out of overt heart failure.
For HCM, the situation is more nuanced. Beta-blockers and certain calcium channel blockers are used to slow the heart rate and ease the stiffness that impairs filling, but they are not targeting the same remodeling cascade as in DCM. The biggest recent advance for obstructive HCM is mavacamten, a first-in-class drug that works by directly inhibiting cardiac myosin, the molecular motor that drives contraction. In the EXPLORER-HCM trial, mavacamten produced substantial reductions in the outflow tract pressure gradient and improved exercise capacity and symptoms compared with placebo.17The Lancet. Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a multicentre, randomised, double-blind, placebo-controlled phase 3 trial These benefits held regardless of whether patients were also taking beta-blockers, though the exercise gains were somewhat blunted in the beta-blocker group, likely because beta-blockers themselves limit heart-rate rise during exertion.18PubMed. Effect of beta-blocker therapy on the response to mavacamten in patients with symptomatic obstructive hypertrophic cardiomyopathy A drug like mavacamten would be potentially lethal in DCM, where contractile strength is already dangerously low; reducing it further could push the patient into cardiogenic shock. Similarly, the vasodilators and afterload-reducing agents central to DCM management could worsen outflow obstruction in HCM by dropping blood pressure and increasing the gradient.
When medications are not enough in obstructive HCM, there are two procedural options: surgical septal myectomy (physically cutting away a strip of the thickened septum) and alcohol septal ablation (injecting alcohol into a small artery feeding the bulging septum to deliberately scar and shrink it). A meta-analysis found that both carry similar long-term mortality, but myectomy achieves a greater reduction in outflow tract gradient and better symptom relief, while ablation has fewer periprocedural complications but a much higher rate of needing a pacemaker and future re-interventions.19PubMed Central. Alcohol Septal Ablation versus Septal Myectomy Treatment of Obstructive Hypertrophic Cardiomyopathy: A Systematic Review and Meta-Analysis A separate meta-analysis found that when follow-up extends beyond five years, ablation may carry higher mortality.20PubMed. Alcohol septal ablation versus surgical septal myectomy of obstructive hypertrophic cardiomyopathy: systematic review and meta-analysis Neither of these procedures has any role in DCM, where the problem is a weak, stretched muscle rather than an obstructing thick one.
Exercise and Lifestyle Advice
For decades, people with HCM were told flatly to avoid vigorous exercise and competitive sports because of the sudden-death association. That advice has softened considerably. More recent data suggest that sudden cardiac arrest during exercise is rare among HCM patients overall, and guidelines now favor an individualized approach: a thorough evaluation followed by shared decision-making between the patient and a specialist, rather than a blanket ban on physical activity.21PubMed. Exercise recommendations for patients with hypertrophic cardiomyopathy Some patients with low-risk profiles can even participate in competitive athletics, though this remains a case-by-case conversation.22PubMed. Athletic Activity for Patients With Hypertrophic Cardiomyopathy and Other Inherited Cardiovascular Diseases: JACC Focus Seminar 3/4
For DCM, exercise recommendations depend heavily on the severity of heart failure. People with well-compensated DCM and stable symptoms are generally encouraged to exercise at moderate intensity, which can improve functional capacity and quality of life. Those with severely reduced ejection fractions or decompensated heart failure need careful supervision. The risk with DCM is less about a sudden electrical event during peak exertion and more about gradually overtaxing a weakened pump or provoking worsening fluid retention.
When HCM Burns Out Into DCM
One of the more confusing clinical scenarios is when HCM transitions into a dilated phase, sometimes called end-stage or “burned-out” HCM. In roughly 5 to 10 percent of HCM patients, the heart eventually dilates and its pumping function deteriorates, making it look superficially like DCM on imaging. This burned-out form tends to be more severe than primary DCM: the fibrosis burden is dramatically higher, with one study reporting roughly 36 percent of the left ventricle replaced by scar tissue in the burned-out HCM group compared with about 13 percent in primary DCM.23Current Health Sciences Journal. Histopathological Aspects of the Myocardium in Dilated Cardiomyopathy – Section: Discussions That degree of scarring explains why end-stage HCM patients generally do not respond to reverse-remodeling therapies the way DCM patients do, and why their prognosis is worse.24PubMed. Distribution of late gadolinium enhancement in end-stage hypertrophic cardiomyopathy and dilated cardiomyopathy: differential diagnosis and prediction of cardiac outcome Heart transplant is often the only remaining option.
This overlap creates diagnostic challenges. If a patient presents for the first time with a dilated, weak heart and no prior imaging showing hypertrophy, distinguishing primary DCM from burned-out HCM requires careful detective work: family history, genetic testing, MRI scar patterns, and sometimes tissue biopsy.
How Common Are They, and Who Gets Them
HCM is the most common inherited cardiomyopathy, with a population prevalence often cited around 1 in 500.25PubMed Central. Hypertrophic Cardiomyopathy and Phenocopies: New Therapies for Old Diseases-Current Evidence and Future Perspectives DCM is less well-defined epidemiologically because it has so many causes, but population-based incidence estimates put idiopathic DCM at roughly 6 per 100,000 person-years, compared with about 2.5 per 100,000 for HCM.26PubMed. Epidemiology of idiopathic dilated and hypertrophic cardiomyopathy. A population-based study in Olmsted County, Minnesota, 1975-1984 Both conditions affect all races and sexes, but U.S. mortality data show that death rates remain highest among older adults, men, and non-Hispanic Black individuals for both diseases. Between 1999 and 2023, there were over 100,000 DCM-related deaths and about 25,000 HCM-related deaths in the United States, with age-adjusted mortality rates declining by roughly 3.5 percent per year for both conditions, likely reflecting improvements in diagnosis and treatment.27International Open Medical Journal. Trends in Mortality Rates for Dilated and Hypertrophic Heart Disease in the United States From 1999 to 2023
Pediatric Differences Worth Knowing
Both conditions can appear in children, but pediatric DCM is biologically distinct from adult DCM in ways that matter for treatment. A study comparing heart tissue from children and adults with DCM found that children show far less of the scar tissue buildup and cell enlargement that define the adult disease. RNA analysis revealed fundamentally different gene-expression profiles, suggesting that the molecular machinery driving DCM in children is not the same as in adults.28PubMed Central. Pediatric and adult dilated cardiomyopathy represent distinct pathological entities This goes a long way toward explaining why the standard adult heart-failure medications, which work by counteracting the remodeling process, do not reliably help children with DCM. Pediatric DCM remains the most common reason for heart transplantation in children, and there is a recognized need for therapies designed specifically for this younger population.
For pediatric HCM, the considerations are somewhat different. Children with HCM are more likely to have a clearly identifiable genetic mutation, and screening of first-degree family members is standard practice. The exercise-restriction conversation is especially fraught in adolescents, where athletic participation carries social and developmental significance beyond just physical fitness.
Look-Alikes That Mimic HCM
Not everything that looks like HCM on an echocardiogram is actually HCM. Several storage and infiltrative diseases can thicken the heart walls in ways that mimic sarcomeric HCM but require entirely different treatment. Cardiac amyloidosis (where abnormal protein deposits infiltrate the heart muscle) and Anderson-Fabry disease (a genetic enzyme deficiency that causes fatty material to accumulate in cells) are the most clinically important phenocopies.29PubMed Central. Diagnostic Clues for the Diagnosis of Nonsarcomeric Hypertrophic Cardiomyopathy (Phenocopies): Amyloidosis, Fabry Disease, and Mitochondrial Disease Identifying these conditions early matters because specific treatments exist for both, including enzyme replacement therapy for Fabry disease and newer drugs targeting amyloid production.30PubMed Central. Hypertrophic Cardiomyopathy and Phenocopies: New Therapies for Old Diseases-Current Evidence and Future Perspectives Giving an HCM medication like mavacamten to someone whose thick heart is actually caused by amyloid would miss the real problem entirely and potentially delay life-saving treatment. This is one reason genetic testing and advanced imaging have become so important: they help cardiologists separate true sarcomeric HCM from its imitators.